Expression of hypoxia-inducible factor-1α protein predicts survival in patients with transitional cell carcinoma of the upper urinary tract

Clinical Cancer Research

Volumn 11, Issue 7, 2005, Pages 2583-2590

  Nakanishi, Kuniaki ^a   Hiroi, Sadayuki ^a   Tominaga, Susumu ^a   Aida, Shinsuke ^a   Kasamatsu, Hiroyasu ^a   Matsuyama, Shigeo ^a   Matsuyama, Tomokazu ^a   Kawai, Toshiaki ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TRANSITIONAL CELL CARCINOMA; URINARY TRACT CARCINOMA; URINARY TRACT TRANSITIONAL CELL CARCINOMA; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARCINOMA, TRANSITIONAL CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL ANALYSIS; TRANSCRIPTION FACTORS; UROLOGIC NEOPLASMS;

EID: 17644415725     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1685     Document Type: Article

References (52)

1. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-87.
2. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
3. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401-9.
4. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA. Relation of neovascularization to metastasis of non-small-cell lung cancer. Lancet 1992;340:145-6.
5. Olivarez D, Ulbright T, DeRiese W, et al. Neovascularization in clinical stage A testicular germ cell tumor: prediction of metastasis disease. Cancer Res 1994;54:2800-2.
6. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
7. Ross R, Raines EW, Bowen-Pope DF. The biology of platelet-derived growth factor. Cell 1986;46:155.
8. Ryan HE, Lo J, Johnson RS. HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J 1998;17:3005-15.
9. Inoue K, Kamada M, Slaton JW, et al. The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Clin Cancer Res 2002;8:1863-70.
10. Ninck S, Reisser C, Dyckhoff G, Helmke B, Bauer H, Herold-Mende C. Expression profiles of angiogenic growth factors in squamous cell carcinomas of the head and neck. Int J Cancer 2003;106:34-44.
11. Sulzbacher I, Birner P, Trieb K, Traxler M, Lang S, Chott A. Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma. Mod Pathol 2003;16:66-71.
12. Mizutani Y, Okada Y, Yoshida O. Expression of platelet-derived endothelial cell growth factor in bladder carcinoma. Cancer 1997;79:1190-4.
13. Maxwell PH, Dachs GU, Gleadle JM, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A 1997;94:8104-9.
14. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A 1993;90:4304-8.
15. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995;270:1230-7.
16. Huang LE, Arany Z, Livingston DM, Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its α subunit. J Biol Chem 1996;271:32253-9.
17. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev 2000;14:34-44.
18. Maxwell PH, Wiesener MS, Chang GW, et al. Thetumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5.
19. An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV, Neckers LM. Stabilization of wild-type p53 by hypoxia-inducible factor 1α. Nature 1998;392:405-8.
20. Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998;394:485-90.
21. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G. Overexpression of hypoxia-inducible factor 1α is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000;60:4693-6.
22. Kuwai T, Kitada Y, Tanaka S, et al. Expression of hypoxia-inducible factor-1α is associated with tumor vascularization in human colorectal carcinoma. Int J Cancer 2003;105:176-81.
23. Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G. Expression of hypoxia-inducible factor 1α in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 2001;7:1661-8.
24. Aebersold DM, Burri P, Beer KT, et al. Expression of hypoxia-inducible factor-1α: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001;61:2911-6.
25. Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 2001;85:881-90.
26. Krishnamachary B, Berg-Dixon S, Kelly B, et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 2003;63:1138-43.
27. Hui EP, Chan AT, Pexxella F, et al. Coexpression of hypoxia-inducible factors 1α and 2α, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 2002;8:2595-604.
28. Bos R, van der Groep P, Greijer AE, et al. Levels of hypoxia-inducible factor-1α independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003;97:1573-81.
29. Beasley NJ, Leek R, Alam M, et al. Hypoxia-inducible factors HIF-1α and HIF-2α in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res 2002;62:2493-7.
30. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 1999;59:5830-5.
31. Gruber G, Greiner RH, Hlushchuk R, et al. Hypoxia-inducible factor 1α in high-risk breast cancer: an independent prognostic parameter? Breast Cancer Res 2004;6:R191-8.
32. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL. Expression of hypoxiainducible factor 1α in brain tumors: association with angiogenesis, invasion, and progression. Cancer 2000 Jun 1;88:2606-18.
33. Theodoropoulos VE, Lazaris AC, Sofras F, et al. Hypoxia-inducible factor 1α expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol 2004;46:200-8.
34. UICC (International Union Against Cancer). Renal pelvis and ureter. In: Illustrated guide to the TNM/pTNM classification of malignant tumours. 3rd ed. 2nd revision. Berlin: Springer-Verlag; 1992. p. 270-3.
35. Murphy WM, Beckwith JB, Farrow GM. Tumors of the kidney, bladder, and related urinary structures. Atlas of tumor pathology, Third Series, fasc. 11. Washington DC: Armed Forces Institute of Pathology; 1994. p. 202-19.
36. Nakanishi K, Kawai T, Torikata C. Immunohistochemical evaluation of p53 oncoprotein in transitional cell carcinoma of the upper urinary tract. Hum Pathol 1996;27:1336-40.
37. Nakanishi K, Tominaga S, Kawai T, Torikata C, Aurues T, Ikeda T. Expression of bcl-2 oncoprotein in transitional cell carcinoma of the upper urinary tract. Virchows Arch 1998;432:445-50.
38. SAS technical report P-217, SAS/STAT software, The PHREG Procedure, version 6. Cary, NC: SAS Institute Inc.; 1991. p. 63.
39. Das AK, Carson CC, Bolick D, Paulson DF. Primary carcinoma of the upper urinary tract. Effect of primary and secondary therapy on survival. Cancer 1990;66:1919-23.
40. Huben RP, Mounzer AM, Murphy GP. Tumor grade and stage as prognostic variables in upper tract urothelial tumors. Cancer 1988;62:2016-20.
41. Nakanishi K, Kawai T, Suzuki M, Torikata C. Growth factors and oncogene products in transitional cell carcinoma. Mod Pathol 1996;9:292-7.
42. Nakanishi K, Kawai T, Sato H, et al. Expression of matrix metalloproteinase-2 (MMP-2) and of membrane-type-1-matrix metalloproteinase (MT1-MMP) in transitional cell carcinoma of the upper urinary tract. Hum Pathol 2000;31:193-200.
43. Nakanishi K, Kawai T, Torikata C, Aurues T, Ikeda T. E-cadherin expression in upper-urinary-tract carcinoma. Int J Cancer 1997;74:446-9.
44. Jones A, Fujiyama C, Blanche C, et al. Relation of vascular endothelial growth factor production to expression and regulation of hypoxia-inducible factor-1α and hypoxia-inducible factor-2α in human bladder tumors and cell lines. Clin Cancer Res 2001;7:1263-72.
45. Ginsberg D, Mechta F, Yaniv M, Oren M. Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci U S A 1991;88:9979-83.
46. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88-91.
47. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531-9.
48. Talks KL, Turley H, Gatter KC, et al. The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000;157:411-21.
49. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 1998;95:7987-92.
50. Leek RD, Talks KL, Pezzella F, et al. Relation of hypoxia-inducible factor-2α (HIF-2α) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in human breast cancer. Cancer Res 2002;62:1326-9.
51. Shima DT, Kuroki M, Deutsch U, Ng YS, Adamis AP, D'Amore PA. The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. J Biol Chem 1996;271:3877-83.
52. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-13.